arginine has been researched along with valsartan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Criscione, L; Lüscher, TF; Novosel, D; Pfeiffer, K; Tschudi, MR | 1 |
| Böger, RH; Maas, R; Quispe-Bravo, S; Schwedhelm, E; Skamira, C | 1 |
| Aslam, S; Leone, A; Santha, T; Wilcox, C | 1 |
| Zoccali, C | 1 |
| Durante, A; Monacelli, F; Odetti, P; Poggi, A; Storace, D; Traverso, N; Viviani, GL | 1 |
| Acikel, C; Caglar, K; Cakir, E; Eyileten, T; Kurt, Y; Oguz, Y; Saglam, M; Sonmez, A; Tasar, M; Vural, A; Yenicesu, M; Yilmaz, MI | 1 |
| Koji, Y; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yoshida, M | 1 |
| Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C | 1 |
| Aydogan, U; Cakir, E; Iyisoy, A; Parlak, A; Saglam, K | 1 |
| Baschiera, F; Botha, J; Brunel, P; Lacy, PS; Prescott, MF; Williams, B | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Shi, FH; Wu, Y; Zhang, YM | 1 |
| Cong, XD; Dai, DZ; Dai, Y; Ding, MJ; Liu, GL; Zhang, YM | 1 |
| Brown, NJ; Gamboa, JL; Ikizler, TA; Pretorius, M; Sprinkel, KC | 1 |
| Huang, Y; Lin, KL; Mei, X; Wang, JR; Zhang, Q | 1 |
| Černe, D; Drevenšek, G; France Štiglic, A; Janić, M; Jerin, A; Lunder, M; Marc, J; Šabovič, M; Skitek, M | 1 |
2 review(s) available for arginine and valsartan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism?
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arginine; Biomarkers; Calcium; Calcium Channel Blockers; Humans; Kidney Failure, Chronic; Risk Factors; Tetrazoles; Valine; Valsartan | 2006 |
6 trial(s) available for arginine and valsartan
| Article | Year |
|---|---|
Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arginine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Female; Humans; Hypertension, Renal; Kidney Failure, Chronic; Male; Methylation; Middle Aged; Oxidative Stress; Renal Dialysis; Tetrazoles; Valine; Valsartan | 2006 |
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Female; Glomerular Filtration Rate; Hemorheology; Humans; Insulin Resistance; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proteinuria; Ramipril; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan; Vasodilation | 2007 |
Effect of telmisartan on forearm postischemic hyperemia and serum asymmetric dimethylarginine levels.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; Endothelium, Vascular; Female; Forearm; Humans; Hyperemia; Hypertension; Male; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 2008 |
Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
Topics: Adult; Aged; Amides; Arginine; Blood Pressure; Demography; Endpoint Determination; Exercise; Female; Fumarates; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Renin; Renin-Angiotensin System; Systole; Tetrazoles; Valine; Valsartan | 2013 |
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arginine; Bradykinin; Cell Line; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ramipril; Renal Dialysis; Valsartan | 2015 |
11 other study(ies) available for arginine and valsartan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arginine; Coronary Vessels; Endothelium, Vascular; Hypertension; Muscle, Smooth, Vascular; Nitric Oxide; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 1994 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Benzimidazoles; Benzoates; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinoprost; Endothelium, Vascular; Humans; Hypertension; Middle Aged; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Renal Insufficiency; Telmisartan; Tetrazoles; Valine; Valsartan | 2005 |
Effects of valsartan therapy on protein glycoxidation.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Arginine; Dinoprost; Female; Glycation End Products, Advanced; Glycosylation; Humans; Hypertension; Lysine; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Proteins; Tetrazoles; Valine; Valsartan | 2006 |
The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Arginine; Benzopyrans; C-Reactive Protein; Ethanolamines; Female; Humans; Hypertension; Male; Middle Aged; Nebivolol; Serum Amyloid P-Component; Tetrazoles; Valine; Valsartan | 2012 |
Hepatosteatosis and hepatic insulin resistance are blunted by argirein, an anti-inflammatory agent, through normalizing endoplasmic reticulum stress and apoptosis in diabetic liver.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Apoptosis; Arginine; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug Combinations; eIF-2 Kinase; Endoplasmic Reticulum Stress; Glucose; Glucose Transporter Type 4; Glutathione Peroxidase; Glycogen; Heat-Shock Proteins; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Receptors, Leptin; Tetrazoles; Transcription Factor CHOP; Valine; Valsartan | 2013 |
Male hypogonadism induced by high fat diet and low dose streptozotocin is mediated by activated endoplasmic reticulum stress and IκBβ and attenuated by argirein and valsartan.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arginine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Combinations; Endoplasmic Reticulum Stress; Hypogonadism; I-kappa B Proteins; Male; Rats; Rats, Sprague-Dawley; Sexual Behavior, Animal; Streptozocin; Tetrazoles; Valine; Valsartan | 2013 |
Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Topics: Amino Acids; Antihypertensive Agents; Arginine; Calorimetry, Differential Scanning; Drug Stability; Excipients; Histidine; Lysine; Powder Diffraction; Solubility; Spectroscopy, Fourier Transform Infrared; Transition Temperature; Valsartan; X-Ray Diffraction | 2017 |
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Cholesterol; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Receptor, Endothelin A; Time Factors; Valsartan; Vasodilation | 2017 |